PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

COVID-19 could cause long-term lung damage, research finds

Research conducted at Oxford University suggests that COVID-19 may be causing lung-damage in patients that can be detected over three months after the initial infection.

The study included ten COVID-19 patients aged between 19 and 69 and used a new scanning technique, dubbed the Xenon technique, to identify lung damage not usually detected on other scans.

This scanning technique uses a gas called Xenon, which patients inhale during MRI scans to show any potential lung damage caused by COVID-19.

Within this study, eight patients had persistent shortness of breath and tiredness three months post-infection and notably had not been admitted to intensive care or required mechanical ventilation.

These patients also had demonstrated no sign of lung damage on conventional scans, according to the BBC.

However, the scans using the Xenon technique found signs of lung damage in the eight patients who had reported breathlessness.

This novel scanning technique was initially developed by researchers at the University of Sheffield, led by Professor James Wild.

The Oxford University study, led by Professor Fergus Gleeson, will continue to test the scanning technique in more COVID-19 patients, with a trial involving up to 100 participants set to be planned.

This study will evaluate the technique and seek to identify whether lung damage can be found in COVID-19 patients who were not admitted to hospital and had not experienced severe symptoms.

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026